deferoxamine has been researched along with Central Hypothyroidism in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| "Hypothyroidism is one of the common endocrine complications described in patients with β-thalassemia major (β-TM)." | 1.51 | Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria. ( Alquobaili, F; Kabalan, Y; Mukhalalaty, Y; Yassouf, MY, 2019) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| "Three patients had evidence of primary hypothyroidism." | 1.29 | Multiple hormone deficiencies in children with hemochromatosis. ( Cassorla, FG; Kamp, GA; Manasco, PK; Munson, PJ; Nienhuis, AW; Oerter, KE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yassouf, MY | 1 |
| Alquobaili, F | 1 |
| Kabalan, Y | 1 |
| Mukhalalaty, Y | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Farmaki, K | 1 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Belhoul, KM | 1 |
| Bakir, ML | 1 |
| Saned, MS | 1 |
| Kadhim, AM | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Ooi, GC | 1 |
| Khong, PL | 1 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Cappellini, MD | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Piga, A | 2 |
| Cnaan, A | 1 |
| De Sanctis, V | 2 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Tuschy, U | 1 |
| Schmidt, U | 1 |
| Meinhold, J | 1 |
| Wutke, K | 1 |
| Oerter, KE | 1 |
| Kamp, GA | 1 |
| Munson, PJ | 1 |
| Nienhuis, AW | 1 |
| Cassorla, FG | 1 |
| Manasco, PK | 1 |
| Calleja, EM | 1 |
| Shen, JY | 1 |
| Lesser, M | 1 |
| Grady, RW | 1 |
| New, MI | 1 |
| Giardina, PJ | 1 |
| Gabutti, V | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Wonke, B | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferoxamine and Central Hypothyroidism
| Article | Year |
|---|---|
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
11 other studies available for deferoxamine and Central Hypothyroidism
| Article | Year |
|---|---|
Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Case-Control Studies; Child; Cross-Sectional Studie | 2019 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine | 2012 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
[Long-term study in congenital refractory anemia and secondary siderosis].
Topics: Adolescent; Anemia, Aplastic; Deferoxamine; Dwarfism; Female; Hemosiderosis; Humans; Hypogonadism; H | 1982 |
Multiple hormone deficiencies in children with hemochromatosis.
Topics: Adolescent; Child; Deferoxamine; Endocrine System Diseases; Female; Follicle Stimulating Hormone; Go | 1993 |
Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Defero | 1998 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |